Chinese Japanese Germany Korea


History Mode of Action A Potential Antiviral for COVID-19?
favipiravir structure
Chemical Name:
T-705;T-705,T705;Favipiravi;Favipiravir;Favipiravjr;Fevipiravir;Unii-ew5gl2X7E0;Favipiravir API;T-705 favipiravir;Favipiravir(T-705)
Molecular Formula:
Formula Weight:
MOL File:

favipiravir Properties

1.78±0.1 g/cm3(Predicted)
storage temp. 
Inert atmosphere,2-8°C
ATC code

favipiravir price More Price(33)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 23384 T-705 ≥98% 259793-96-9 1mg $26 2021-12-16 Buy
Cayman Chemical 23384 T-705 ≥98% 259793-96-9 5mg $98 2021-12-16 Buy
Tocris 7225 Favipiravir ≥98%(HPLC) 259793-96-9 50 $135 2021-12-16 Buy
TRC F103350 Favipiravir 259793-96-9 100mg $150 2021-12-16 Buy
TRC F103350 Favipiravir 259793-96-9 25mg $85 2021-12-16 Buy

favipiravir Chemical Properties,Uses,Production


Favipiravir is a broad-spectrum antiviral drug that was cleared by the Drugs Controller General of India (DCGI) last week for “emergency restricted” use among Covid-19 patients. Glenmark will sell the generic favipiravir under the brand name FabiFlu.
Favipiravir was originally developed in the late 1990s by a company that was later purchased by the Japanese firm Fujifilm as part of its transition from the photo business to healthcare. After being tested against a range of viruses, the drug was approved in Japan in 2014 for emergency use against flu epidemics or to treat new strains of influenza.

Mode of Action

Favipiravir inhibits the RNA-dependent RNA polymerase (RdRp) — an enzyme that allows the coronavirus to replicate inside host cells.Inside the cells, favipiravir is converted to favipiravir ribofuranosyl-5′-triphosphate (favipiravir-RTP) by host cells. This molecule then blocks the RdRp enzyme of SARS-CoV-2, the virus that causes Covid-19.According to a statement by Glenmark, favipiravir works only during the earlier stages of the disease, when the viral replication is higher, but the body's immune response has not gone into overdrive.
Metabolism of favipiravir to its triphosphate form occurs in an extracellular environment in a concentration-dependent manner. The vRNA polymerase mistakenly recognizes favipiravir-RTP as a purine nucleotide. This favipiravir-RTP is misincorporated in nascent vRNA, or it may act by binding to conserved polymerase domains, preventing incorporation of nucleotides for vRNA replication and transcription (Jin et al., 2013).

A Potential Antiviral for COVID-19?

Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild or moderate courses, up to 5%–10% can have severe, potentially life threatening course, there is an urgent need for effective drugs. Optimized supportive care remains the mainstay of therapy.
There have been more than 300 clinical trials going on, various antiviral and immunomodulating agents are in various stages of evaluation for COVID-19 in those trials and some of them will be published in the next couple of months. Despite the urgent need to find an effective antiviral treatment for COVID-19 through randomized controlled studies, certain agents are being used all over the world based on either in-vitro or extrapolated evidence or observational studies. The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as they have recently been reported to have an activity against SARS-CoV-2 in vitro and are licensed for the treatment of some other human infections.


Favipiravir,  6-fluoro-3-hydroxypyrazine-2-carboxamide, is a new broad-spectrum antiviral drug targeting RNA-dependent RNA polymerase (RdRp) developed by Japan's Toyama Chemical Pharmaceutical Company. It was approved for marketing in Japan in March 2014 for the treatment of new and recurrent influenza. During the outbreak of the new coronavirus, the results of the Phase I clinical study of the drug published in March 2020 showed that the drug may have the effect of speeding up virus clearance to alleviate the progress of new coronavirus pneumonia.


Favipiravir can be used for antiviral treatment of influenza A and B. Studies have shown that in addition to influenza virus, the drug also exhibits good antiviral activity against a variety of RNA viruses, such as Ebola virus, arena virus, Bunia virus, and rabies virus.


Favipiravir is used for the treatment of advanced Ebola virus infection in a small animal model. Favipiravir suppressed the replication of Zaire Ebola virus and prevented a lethal outcome in 100% of the animals. Based on the studies, Favipiravir can be a candidate for the treatment of Ebola hemorrhagic fever. It is a COVID19-related research product.

Mechanism of action

Favipiravir is an antiviral drug that selectively inhibited the RdRP of influenza virus. It showed specific activity against all three influenza A, B, and C (Furuta et al., 2013). It also inhibited the RV replication in HeLa cells, with an EC50 of 29 μg/mL (Furuta et al., 2002). Analysis showed that the primary mechanism of action of favipiravir against the influenza virus was specific inhibition of vRNA polymerase (Furuta et al., 2005). It is predicted that a similar mechanism might occur with other viruses, such as PV and RV, inhibited by favipiravir, which may account for its broad-spectrum inhibition. Mechanistic studies show that the favipiravir and its form favipiravir-RMP (favipiravir-ribofuranosyl-50-monophosphate) do not inhibit influenza RNA polymerase activity, but it is the phosphoribosylated form, favipiravir-ribofuranosyl-50-triphosphate (RTP) that inhibits the enzyme. 

Chemical Synthesis

645 grams of sodium hydroxide were dissolved in 9L of water, the temperature was lowered to 5°C, and 1.29 kg of 6-fluoro-3-hydroxy-2-cyanopyrazine was added in batches, stirred, and heated slightly, and the temperature of the reaction system was controlled to -10°C, it takes 3.5 hours to complete the addition, after holding for 1 hour, the temperature is raised to 40°C for 1 hour. Add 100g of activated carbon to the reaction solution, hot filter, cool the mother liquor to 5°C, adjust the pH to 3-4 with concentrated hydrochloric acid, precipitate a large amount of solids, filter and dry to obtain a crude off-white powder, beaten with 2.8 liters of 15% methanol aqueous solution and filter After drying, 1.34 kg of white powder favipiravir was obtained. 1H-NMR (DMSO, 600MHz): δ 13.38 (s, 1H), 8.73 (1s, 1H), 8.51-8.49 (d, J=12, 2H) (yield 91%).

favipiravir Preparation Products And Raw materials

Raw materials

Preparation Products

favipiravir Suppliers

Global( 337)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Hebei Senko Biotechnology Co., Ltd.
0086-133 3137 7233 CHINA 289 58
Jinan Chenghui-Shuangda Chemical Co.,Ltd
+86-531-58897093 CHINA 158 58
Shaanxi Dideu Medichem Co. Ltd
029-88380327 CHINA 3994 58
86-18523575427 China 47498 58
Beijing Yibai Biotechnology Co., Ltd
0086-182-6772-3597 CHINA 420 58
Hebei Binshare New Material Co. Ltd
+8618633865755 +86-86-18633865755 CHINA 987 58
Handan Tongyi New Material Technology Co., Ltd
+8617330042575 CHINA 341 58
Nanjing Fred Technology Co., Ltd.
15380713688 +86-02584696168 CHINA 866 58
Guangzhou Biocar Biotechnology Co.,Ltd.
027-86589876 China 369 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 China 22607 55

Related articles

  • What is Favipiravir?
  • Favipiravir is a pyrazine carboxamide derivative developed by Toyama Chemical of Japan to act against many RNA viruses. It was....
  • Jul 21,2020

View Lastest Price from favipiravir manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2022-01-17 Favipiravir
US $1.00 / g 10g 99.5% 1000kg Guangzhou Biocar Biotechnology Co.,Ltd.
2022-01-17 favipiravir
US $65.00 / KG 1KG 99% 20 tons Hanhong Medicine Technology (Hubei) Co., Ltd.
2022-01-10 Favipiravi
US $100.00 / Kg/Bag 1KG 99% 10Tons Hebei Senko Biotechnology Co., Ltd.

259793-96-9(favipiravir)Related Search:

  • Pyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo- (9CI)
  • Favipiravir
  • Unii-ew5gl2X7E0
  • 6-fluoro-3,4-dihydro-3-oxo-Pyrazinecarboxamide
  • 6-fluoro-3,4-dihydro-3-oxo- (9CI)
  • T-705
  • 6-Fluoro-3-hydroxypyrazine-2-carboxamide
  • 2-PyrazinecarboxaMide, 6-fluoro-3,4-dihydro-3-oxo-
  • 6-Fluoro-3-oxo-3,4-dihydropyrazine-2-carboxaMide
  • PyrazinecarboxaMide, 6-fl...
  • T-705 favipiravir
  • T-705,T705
  • 6-Fluoro-3,4-dihydro-3-oxo-pyrazinecarboxaMide 95%
  • Favipiravi
  • Favipiravjr
  • T 705; FAVIPIRAVIR;T-705;T705
  • 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide
  • 6-Fluoro-3-hydroxypyrazine-2-carboxamide favipiravir
  • Favipiravir(T-705)
  • Favipiravir API
  • 6-Fluoro-3,4-dihydro-3-oxo-2-pyrazinecarboxamide
  • favipiravir 6-fluoro-3-hydroxypyrazine-2-carboxamide
  • The method of villa wei
  • Favipiravir (This product is unavailable in the U.S.)
  • 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide
  • favipiravir USP/EP/BP
  • Fevipiravir
  • 5-Fluoro-2-oxo-1H-pyrazine-3-carboxamide, 95+%
  • 259793-96-9
  • API
Copyright 2017 © ChemicalBook. All rights reserved